The invention concerns vitronectin receptor antagonist compounds of formula
(3): R.sub.1 --Y--A--B--D--E--F--G wherein R.sub.1, Y, A, B, D, E, F, and
G are as defined in the description, their physiologically acceptable
salts and their prodrugs, methods for preparing compounds of formula (I),
their use, in particular as medicine and pharmaceutical compositions
containing them.
